Sugi Predict

Sugi Predict / Compounds / SCHEMBL597569

SCHEMBL597569

SCHEMBL597569

C=CCC1(O)C=CC(C[C@H](N)C(=O)O)=CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.33
▸ PKM P14618 2/20 0.33
▸ PTGS1 P23219 2/20 0.33
▸ ALPI P09923 1/20 0.33
▸ XIAP P98170 1/20 0.33
▸ GRIK1 P39086 2/20 0.32
▸ GRIK2 Q13002 2/20 0.32
▸ USP2 O75604 3/20 0.31
▸ ALOX15 P16050 2/20 0.31
▸ HIF1A Q16665 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ RECQL P46063 2/20 0.31
▸ TDP1 Q9NUW8 2/20 0.31
▸ RGS12 O14924 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ CASP1 P29466 1/20 0.31
▸ BRCA1 P38398 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267236 0.83 SLC7A5 (0.37) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL21411541 0.80 SLC7A5 (0.34) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL125178 0.80 SLC7A5 (0.34) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL93817 0.79 SLC7A5 (0.33) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL4262731 0.79 SLC7A5 (0.40) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL8740472 0.77 SLC7A5 (0.39) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL7200971 0.77 SLC7A5 (0.39) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL1614571 0.76 SLC7A5 (0.38) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL3284389 0.76 SLC7A5 (0.38) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL28669915 0.76 SLC7A5 (0.38) SLC7A5PKMPTGS1ALPIXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4199968-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF Ambrx, Inc. (US) 2023-06-28 — — EP claimed
WO-2022040596-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2022-02-24 — — WO claimed
EP-1490483-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS The Scripps Research Institute (US) 2004-12-29 — — EP claimed
US-20030082575-A1 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2003-05-01 — — US claimed
WO-2002085923-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-10-31 — — WO claimed
EP-4117732-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF Ambrx, Inc. (US) 2023-01-18 — — EP disclosed
WO-2021183832-A1 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF AMBRX, INC. (US) 2021-09-16 — — WO disclosed
EP-2796546-B1 Incorporation of unnatural amino acids SCRIPPS RESEARCH INST (US) 2017-08-09 — — EP disclosed
EP-1490483-B1 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS SCRIPPS RESEARCH INST (US) 2015-06-03 — — EP disclosed
EP-2322631-B1 Methods and compositions for the prodcution of orthogonal tRNA-aminoacyl-tRNA synthetase pairs SCRIPPS RESEARCH INST (US) 2014-11-12 — — EP disclosed
EP-2796546-A1 In vivo incorporation of unnatural amino acids The Scripps Research Institute (US) 2014-10-29 — — EP disclosed
US-20120202243-A1 IN Vivo Incorporation of Unnatural Amino Acids THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-09 — — US disclosed
US-7368275-B2 Orthogonal tRNA synthetase that aminoacylates with reduced efficiency; lower km and recognizes selector codon in mRNA THE SCRIPPS RESEARCH INSTITUTE (US) 2008-05-06 — — US disclosed
US-20070117184-A1 Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins THE SCRIPPS RESEARCH INSTITUTE 2007-05-24 — — US disclosed
US-20060233744-A1 Orthogonal tRNA synthetase that aminoacylates with reduced efficiency; lower km and recognizes selector codon in mRNA THE SCRIPPS RESEARCH INSTITUTE 2006-10-19 — — US disclosed
US-7045337-B2 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2006-05-16 — — US disclosed
US-20050250183-A1 In vivo incorporation of unnatural amino acids THE SCRIPPS RESEARCH INSTITUTE (US) 2005-11-10 — — US disclosed
EP-1490483-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS The Scripps Research Institute (US) 2004-12-29 — — EP disclosed
US-20030082575-A1 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2003-05-01 — — US disclosed
WO-2002085923-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250183-A1 In vivo incorporation of unnatural amino acids BCAT1, AADAT, NPEPPS SLC7A5 16/4885PKM 2702/4885PTGS1 4488/4885
US-20060233744-A1 Orthogonal tRNA synthetase that aminoacylates with reduced efficiency; lower km and recognizes selector codon in mRNA AARS1, NSUN3, KARS1 SLC7A5 289/4885PKM 1722/4885PTGS1 4168/4885
US-20070117184-A1 Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins AARS1, NSUN3, TRMT1 SLC7A5 223/4885PKM 3459/4885PTGS1 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.